Interactions between oral antineoplastic agents and concomitant medication: A systematic review

Expert Opinion on Drug Safety

Volumn 12, Issue 3, 2013, Pages 403-420

  Carcelero, Esther ^a   Anglada, Helena ^a   Tuset, Montse ^a   Creus, Natalia ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Antitumoral agents; Drug interactions; Pharmacodynamics; Pharmacokinetics

Indexed keywords

5 (2 BROMOVINYL) 2' DEOXYURIDINE; AMLODIPINE; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIMYCOBACTERIAL AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; BUSULFAN; CALCIUM; CARDIOVASCULAR AGENT; CIPROFLOXACIN; CLARITHROMYCIN; DASATINIB; ERLOTINIB; ERYTHROMYCIN; ESTRAMUSTINE; EVEROLIMUS; FLUOROURACIL; GEFITINIB; IMATINIB; KETOCONAZOLE; METHOTREXATE; METRONIDAZOLE; NAVELBINE; PENICILLIN DERIVATIVE; RITONAVIR; SIMVASTATIN; SORAFENIB; SUNITINIB; UNINDEXED DRUG;

ANTIVIRAL THERAPY; AREA UNDER THE CURVE; BLOOD CLOTTING; CANCER CHEMOTHERAPY; CANCER PATIENT; CHRONIC MYELOID LEUKEMIA; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG FATALITY; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG WITHDRAWAL; FOOD DRUG INTERACTION; GRAFT VERSUS HOST REACTION; HEMATOPOIESIS; HUMAN; HYPERTRANSAMINASEMIA; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAXIMUM PERMISSIBLE DOSE; MAXIMUM PLASMA CONCENTRATION; MILK; MUCOSA INFLAMMATION; NEUTROPENIA; PERIPHERAL NEUROPATHY; PLASMA CONCENTRATION-TIME CURVE; PROPHYLAXIS; RECOMMENDED DRUG DOSE; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; THROMBOSIS; VITAMIN SUPPLEMENTATION;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS;

EID: 84876538546     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2013.784268     Document Type: Review

References (97)

1. European Medicines Agency: summary of product characteristics. Available from: http://www.ema.europa.eu/ema/index.jsp curl=pages/medicines/landing/epar- search.jsp&mid=WC0b01ac058001d124 [Last accessed 29 November 2012]
2. Klasco RK. DRUGDEX-System (electronic version). Thomson Micromedex, Greenwood Village, Colorado, USA. 2012. Available from: http://www.thomsonhc.com [Last accessed 20 Jun 2012]
3. Lacy CF, Armstrong LL, Goldman MP, Lance LL. Drug information handbook. 20th edition. Lexi-Comp, Inc; Hudson, Ohio: 2011
4. FDA Drug development and drug interactions. Tables of Substrates, Inhibitors and Inducers (Updated 28 July 2011). Available from: http://www.fda. gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ DrugInteractionsLabeling/ucm080499. htm [Last accessed 1 September 2012]
5. Zarychanski R, Wlodarczyk K, Ariano R, Bow E. Pharmacokinetic interaction between methotrexate and piperacillin/tazobactam resulting in prolonged toxic concentrations of methotrexate. J Antimicrob Chemother 2006;58:228-30 (Pubitemid 44295021)
6. Yamamoto K, Sawada Y, Matsushita Y, et al. Delayed elimination of methotrexate associated with piperacillin administration. Ann Pharmacother 1997;31:1261-2 (Pubitemid 27431080)
7. Takeda M, Khamdang S, Narikawa S, et al. Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther 2002;302:666-71 (Pubitemid 34787234)
8. Yano R, Tani D, Watanabe K, et al. Evaluation of potential interaction between vinorelbine and clarithromycin. Ann Pharmacother 2009;43:453-8
9. Kovarik JM, Beyer D, Bizot MN, et al. Effect of multiple-dose erythromycin on everolimus pharmacokinetics. Eur J Clin Pharmacol 2005;61:35-8 (Pubitemid 40558277)
10. Nilsson C, Aschan J, Hentschke P, et al. The effect of metronidazole on busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 2003;31:429-35 (Pubitemid 36511807)
11. FDA Drug development and drug interactions. Guidance for industry. Drug Interaction Studies-Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations. (Updated February 2012). Available from: http://www.fda.gov/downloads/Drugs/Guidance ComplianceRegulatoryInformation/ Guidances/UCM292362.pdf [Last accessed 3 March 2013]
12. Lathia C, Lettieri J, Cihon F, et al. Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics. Cancer Chemother Pharmacol 2006;57:685-92
13. van Erp NP, Gelderblom H, Karlsson MO, et al. Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib. Clin Cancer Res 2007;13:7394-400
14. Baena-Cañada JM, Mart́nez MJ, Garća-Olmedo O, et al. Interaction between capecitabine and brivudin in a patient with breast cancer. Nat Rev Clin Oncol 2010;7:55-8
15. Rätz Bravo AE, Hofer S, Krähenbühl S, Ludwig C. Fatal drug-drug interaction of brivudine and capecitabine. Acta Oncol 2009;48:631-3
16. Tolcher AW, Appleman LJ, Shapiro GI, et al. A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer. Cancer Chemother Pharmacol 2011;67:751-64
17. Bello CL, Mulay M, Huang X, et al. Electrocardiographic characterization of the QTc interval in patients with advanced solid tumors: pharmacokinetic- pharmacodynamic evaluation of sunitinib. Clin Cancer Res 2009;15:7045-52
18. Veeraputhiran M, Sundermeyer M. Rhabdomyolysis resulting from pharmacologic interaction between erlotinib and simvastatin. Clin Lung Cancer 2008;9:232-4
19. O'Brien SG, Meinhardt P, Bond E, et al. Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia. Br J Cancer 2003;89:1855-9 (Pubitemid 37533259)
20. Wakelee HA, Takimoto CH, Lopez-Anaya A, et al. The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol 2012;69:563-71
21. Gomo C, Coriat R, Faivre L, et al. Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. Invest New Drugs 2011;29:1511-14
22. Ross DM. Peripheral neuropathy on imatinib treatment for chronic myeloid leukaemia: suspected adverse drug interaction with amlodipine. Intern Med J 2009;39:708
23. Wang Y, Zhou L, Dutreix C, et al. Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia. Br J Clin Pharmacol 2008;65:885-92 (Pubitemid 351677440)
24. Swaisland HC, Ranson M, Smith RP, et al. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol. Clin Pharmacokinet 2005;44:1067-81 (Pubitemid 41356392)
25. Kovarik JM, Beyer D, Bizot MN, et al. Pharmacokinetic interaction between verapamil and everolimus in healthy subjects. Br J Clin Pharmacol 2005;60:434-7 (Pubitemid 41428475)
26. Ridruejo E, Cacchione R, Villamil AG, et al. Imatinib-induced fatal acute liver failure. World J Gastroenterol 2007;13:6608-11
27. Kim DW, Tan EY, Jin Y, et al. Effects of imatinib mesylate on the pharmacokinetics of paracetamol (paracetamol) in Korean patients with chronic myelogenous leukaemia. Br J Clin Pharmacol 2011;71:199-206
28. Uwai Y, Taniguchi R, Motohashi H, et al. Methotrexate-loxoprofen interaction: involvement of human organic anion transporters hOAT1 and hOAT3. Drug Metab Pharmacokinet 2004;19:369-74
29. El-Sheikh AA, van den Heuvel JJ, Koenderink JB, Russel FG. Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2-and MRP4/ABCC4-mediated methotrexate transport. J Pharmacol Exp Ther 2007;320:229-35 (Pubitemid 46025738)
30. Cassano WF. Serious methotrexate toxicity caused by interaction with ibuprofen. Am J Pediatr Hematol Oncol 1989;11:481-2 (Pubitemid 20020010)
31. Skeith KJ, Russell AS, Jamali F, et al. Lack of significant interaction between low dose methotrexate and ibuprofen or flurbiprofen in patients with arthritis. J Rheumatol 1990;17:1008-10 (Pubitemid 20278014)
32. Smith DA, Koch KM, Arya N, et al. Effects of ketoconazole and carbamazepine on lapatinib pharmacokinetics in healthy subjects. Br J Clin Pharmacol 2009;67:421-6
33. Kovarik JM, Hartmann S, Figueiredo J, et al. Effect of rifampin on apparent clearance of everolimus. Ann Pharmacother 2002;36:981-5 (Pubitemid 34564379)
34. Reardon DA, Vredenburgh JJ, Desjardins A, et al. Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. J Neurooncol 2011;101:57-66
35. Pursche S, Schleyer E, von Bonin M, et al. Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. Curr Clin Pharmacol 2008;3:198-203
36. Brickell K, Porter D, Thompson P. Phenytoin toxicity due to fluoropyrimidines (5FU/capecitabine): three case reports. Br J Cancer 2003;89:615-16 (Pubitemid 37076161)
37. Grenader T, Gipps M, Shavit L, Gabizon A. Significant drug interaction: phenytoin toxicity due to erlotinib. Lung Cancer 2007;57:404-6 (Pubitemid 47285413)
38. Azoulay L, Dell'Aniello S, Huiart L, et al. Concurrent use of tamoxifen with CYP2D6 inhibitors and the risk of breast cancer recurrence. Breast Cancer Res Treat 2011;126:695-703
39. Lash TL, Pedersen L, Cronin-Fenton D, et al. Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram. Br J Cancer 2008;99:616-21
40. Dezentjé VO, Guchelaar HJ, Nortier JW, et al. Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer. Clin Cancer Res 2009;15:15-21
41. Aubert RE, Stanek EJ, Yao J, et al. Risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors [abstract CRA508]. J Clin Oncol 2009;27:S18
42. Desmarais JE, Looper KJ. Interactions between tamoxifen and antidepressants via cytochrome P450 2D6. J Clin Psychiatry 2009;70:1688-97
43. Eley T, Luo FR, Agrawal S, et al. Phase I study of the effect of gastric acid pH modulators on the bioavailability of oral dasatinib in healthy subjects. J Clin Pharmacol 2009;49:700-9
44. Yin OQ, Gallagher N, Fischer D, et al. Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib. J Clin Pharmacol 2010;50:960-7
45. Flaherty KT, Lathia C, Frye RF, et al. Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol 2011;68:1111-18
46. Yin OQ, Giles FJ, Baccarani M, et al. Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia. Cancer Chemother Pharmacol 2012;70:345-50
47. Duong S, Leung M. Should the concomitant use of erlotinib and acid-reducing agents be avoided The drug interaction between erlotinib and acid-reducing agents. J Oncol Pharm Pract 2011;17:448-52
48. Vincenzi B, Tonini G, Santini D. Aprepitant for erlotinib-induced pruritus. N Engl J Med 2010;363:397-8
49. Witten J, Frederiksen PL, Mouridsen HT. The pharmacokinetics of cyclophosphamide in man after treatment with allopurinol. Acta Pharmacol Toxicol 1980;46:392-4 (Pubitemid 10106143)
50. Boston Collaborative Drug Surveillence Program. Allopurinol and cytotoxic drugs. Interaction in relation to bone marrow depression. JAMA 1974;227:1036
51. Stolbach L, Begg C, Bennett JM, et al. Evaluation of bone marrow toxic reaction in patients treated with allopurinol. JAMA 1982;247:334-6 (Pubitemid 12203020)
52. Lum BL, Kaubisch S, Yahanda AM, et al. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 1992;10:1635-42 (Pubitemid 23057994)
53. Pea F, Damiani D, Michieli M, et al. Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. Eur J Clin Pharmacol 1999;55:361-8 (Pubitemid 29344079)
54. Jansman FG, Reyners AK, van Roon EN, et al. Scientific Institute for Dutch Pharmacists (WINAp); Dutch Society for Medical Oncology (NVMO); Dutch Society of Clinical Pharmacology and Biopharmacy (NVKF&B). Consensus-based evaluation of clinical significance and management of anticancer drug interactions. Clin Ther 2011;33:305-14
55. Fox RI, Morgan SL, Smith HT, et al. Combined oral cyclosporin and methotrexate therapy in patients with rheumatoid arthritis elevates methotrexate levels and reduces 7-hydroxymethotrexate levels when compared with methotrexate alone. Rheumatology 2003;42:989-94 (Pubitemid 37220969)
56. Kovarik JM, Kalbag J, Figueiredo J, et al. Differential influence of two cyclosporine formulations on everolimus pharmacokinetics: a clinically relevant pharmacokinetic interaction. J Clin Pharmacol 2002;42:95-9 (Pubitemid 34038374)
57. Kovarik JM, Curtis JJ, Hricik DE, et al. Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. Transplant Proc 2006;38:3456-8 (Pubitemid 44908476)
58. Mulder KE, Egorin MJ, Sawyer MB. Renal dysfunction in a renal transplant patient treated concurrently with cyclosporine and imatinib. Invest New Drugs 2012;30:2400-2
59. Anderlini P, Sheth S, Hicks K, et al. Re: imatinib mesylate administration in the first 100 days after stem cell transplantation. Biol Blood Marrow Transplant 2004;10:883-4 (Pubitemid 39625310)
60. Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 2009;158:693-705
61. Lepist EI, Ray AS. Renal drug-drug interactions: what we have learned and where we are going. Expert Opin Drug Metab Toxicol 2012;8:433-48
62. US Foos and Drug Administration: summary of product characteristics. Available from: http://www.accessdata. fda.gov/scripts/cder/drugsatfda/index.cfm [Last accessed 03 March 2013]
63. Buggia I, Zecca M, Alessandrino EP, et al. Itraconazole can increase systemic exposure to busulfan in patients given bone marrow transplantation. Anticancer Res 1996;16:2083-8 (Pubitemid 26270729)
64. Johnson FM, Agrawal S, Burris H, et al. Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors. Cancer 2010;116:1582-91
65. Rakhit A, Pantze MP, Fettner S, et al. The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP-) predicts in vivo metabolic inhibition. Eur J Clin Pharmacol 2008;64:31-41
66. Yong WP, Desai AA, Innocenti F, et al. Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer. Cancer Chemother Pharmacol 2007;60:811-19 (Pubitemid 47389387)
67. Kovarik JM, Beyer D, Bizot MN, et al. Blood concentrations of everolimus are markedly increased by ketoconazole. J Clin Pharmacol 2005;45:514-18 (Pubitemid 40562941)
68. Kamdem LK, Flockhart DA, Desta Z. In vitro cytochrome P450-mediated metabolism of exemestane. Drug Metab Dispos 2011;39:98-105
69. Dutreix C, Peng B, Mehring G, et al. Pharmacokinetic interaction between ketoconazole and imatinib mesylate in healthy subjects. Cancer Chemother Pharmacol 2004;54:290-4 (Pubitemid 39304422)
70. Gambillara E, Laffitte E, Widmer N, et al. Severe pustular eruption associated with imatinib and voriconazole in a patient with chronic myeloid leukaemia. Dermatology 2005;211:363-5 (Pubitemid 41642114)
71. Takahashi N, Miura M, Kameoka Y, et al. Drug interaction between lenalidomide and itraconazole. Am J Hematol 2012;87:338-9
72. Washington C, Eli M, Bello C, et al. The effect of ketoconazole, a potent CYP3A4 inhibitor, on SU011248 pharmacokinetics in caucasian and Asian healthy subjects [abstr no. 553]. Proc Am Soc Clin Oncol 2003;22
73. Rigas JR, Francis PA, Muindi JR, et al. Constitutive variability in the pharmacokinetics of the natural retinoid, all-trans-retinoic acid, and its modulation by ketoconazole. J Natl Cancer Inst 1993;85:1921-6 (Pubitemid 23354030)
74. Vanier KL, Mattiussi AJ, Johnston DL. Interaction of all-trans-retinoic acid with fluconazole in acute promyelocytic leukemia. J Pediatr Hematol Oncol 2003;25:403-4 (Pubitemid 36569973)
75. Bennett MT, Sirrs S, Yeung JK, Smith CA. Hypercalcemia due to all trans retinoic acid in the treatment of acute promyelocytic leukemia potentiated by voriconazole. Leuk Lymphoma 2005;46:1829-31 (Pubitemid 43203121)
76. Dixon KS, Hassoun A. Pseudotumor cerebri due to potentiation of all-trans retinoic acid by voriconazole. J Am Pharm Assoc 2010;50:742-4
77. Brave M, Goodman V, Kaminskas E, et al. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clin Cancer Res 2008;14:352-9 (Pubitemid 351226100)
78. Abbas R, Fettner S, Riek M, et al. A drug-drug interaction study to evaluate the effect of rifampicin on the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib in healthy subjects [abstract 548]. Proc Am Soc Clin Oncol 2003;22:137
79. Aromasil-(exemestane tablets). Agencia Española de Medicamentos y Productos Sanitarios.: summary of product characteristics. Available from: http://www.aemps.gob.es/cima/fichasTecnicas. dometodo=detalleForm [Last accessed 11 January 2012]
80. Bolton AE, Peng B, Hubert M, et al. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. Cancer Chemother Pharmacol 2004;53:102-6 (Pubitemid 38186987)
81. Keating GM, Santoro A. Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs 2009;69:223-40
82. Bello C, Houk B, Sherman L, et al. Effect of rifampin on the pharmacokinetics of sunitinib malate (SU11248) in Caucasian and Japanese populations [abstract 430]. 13th European Cancer Conference; Paris; 2005
83. Kivisto KT, Villikka K, Nyman L, et al. Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin. Clin Pharmacol Ther 1998;64:648-54 (Pubitemid 29011384)
84. Yates RA, Wong J, Seiberling M, et al. The effect of anastrozole on the single-dose pharmacokinetics and anticoagulant activity of warfarin in healthy volunteers. J Clin Pharmacol 2001;51:429-35 (Pubitemid 32852980)
85. Janney LM, Waterbury NV. Capecitabine-Warfarin Interaction. Ann Pharmacother 2005;39:1546-51 (Pubitemid 41197140)
86. Seifter EJ, Brooks BJ. Jr, Urba WJ. Possible interactions between warfarin and antineoplastic drugs. Cancer Treat Rep 1985;69:244-5 (Pubitemid 15170473)
87. Eulexin-(flutamide) tablets [product Information]. Schering Corporation; Kenilworth, NJ: 1999
88. Quintás-Cardama A, Han X, Kantarjian H, et al. Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Blood 2009;114:261-3
89. Arai S, Mitsufuji H, Nishii Y, et al. Effect of gefitinib on warfarin antithrombotic activity. Int J Clin Oncol 2009;14:332-6
90. Thomas KS, Billingsley A, Amarshi N, et al. Elevated international normalized ratio associated with concomitant warfarin and erlotinib. Am J Health Syst Pharm 2010;67:1426-9
91. Moretti LV, Montalvo RO. Elevated International Normalized Ratio associated with concurrent use of sorafenib and warfarin. Am J Health Syst Pharm 2009;66:2123-5
92. Breccia M, Santopietro M, Logisci G, et al. Concomitant use of imatinib and warfarin in chronic phase chronic myeloid leukemia patients does not interfere with drug efficacy. Leuk Res 2010;34:e224-5
93. Yin OQ, Gallagher N, Fischer D, et al. Effects of nilotinib on single-dose warfarin pharmacokinetics and pharmacodynamics: a randomized, single-blind, two-period crossover study in healthy subjects. Clin Drug Investig 2011;31:169-79
94. Givens CB, Bullock LN, Franks AS. Safety of concomitant tamoxifen and warfarin. Ann Pharmacother 2009;43:1867-71
95. Sparano BA, Egorin MJ, Parise RA, et al. Effect of antacid on imatinib absorption. Cancer Chemother Pharmacol 2009;63:525-8
96. Egorin MJ, Shah DD, Christner SM, et al. Effect of a proton pump inhibitor on the pharmacokinetics of imatinib. Br J Clin Pharmacol 2009;68:370-4
97. Sviland L, Robinson A, Proctor SJ, Bateman DN. Interaction of cimetidine with oral melphalan. A pharmacokinetic study. Cancer Chemother Pharmacol 1987;20:173-5